| 1 |
35001019 | Effects of CYP2C19*17 genetic polymorphisms on plasma and saliva concentrations of diazepam in patients with alcohol withdrawal syndrome. | 2022 Apr 1 |
3 |
| 2 |
34720165 | Effects of CYP2C19*17 Genetic Polymorphisms on the Steady-State Concentration of Diazepam in Patients With Alcohol Withdrawal Syndrome. | 2021 Oct |
3 |
| 3 |
32134726 | How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome? | 2020 Mar 5 |
6 |
| 4 |
27099220 | Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population. | 2016 Jul |
2 |
| 5 |
27991432 | The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-13C breath test in GERD patients: clinical relevance for personalized medicine. | 2016 Dec 17 |
1 |
| 6 |
26020462 | Extreme Duration of Diazepam-Associated Sedation in a Patient With Alcohol Delirium and CYP2C19 Polymorphisms. | 2015 Aug |
1 |
| 7 |
26159874 | CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine. | 2015 Sep |
1 |
| 8 |
28520370 | Diazepam Therapy and CYP2C19 Genotype | 2012 |
1 |
| 9 |
20468063 | Association between CYP2C19 polymorphism and depressive symptoms. | 2010 Sep |
4 |
| 10 |
19571432 | Simultaneous expression of plural forms of human cytochrome P450 at desired ratios in HepG2 cells: adenovirus-mediated tool for cytochrome P450 reconstitution. | 2009 |
1 |
| 11 |
18076219 | Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. | 2008 |
1 |
| 12 |
18175099 | Midazolam and other benzodiazepines. | 2008 |
1 |
| 13 |
17375979 | The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. | 2007 |
1 |
| 14 |
17635335 | Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. | 2007 Aug |
1 |
| 15 |
29788670 | Personalized medicine for eradication of Helicobacter pylori. | 2007 Aug |
1 |
| 16 |
16307177 | Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation. | 2006 |
1 |
| 17 |
16771600 | The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. | 2006 |
1 |
| 18 |
16338280 | CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. | 2005 Dec |
2 |
| 19 |
12708941 | Phenytoin-diazepam interaction. | 2003 May |
1 |
| 20 |
12869636 | Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. | 2003 Aug |
1 |
| 21 |
11927837 | Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. | 2002 Apr |
1 |
| 22 |
12222994 | Clinical significance of the cytochrome P450 2C19 genetic polymorphism. | 2002 |
1 |
| 23 |
12464799 | Identification and functional characterization of new potentially defective alleles of human CYP2C19. | 2002 Dec |
1 |
| 24 |
11510629 | Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. | 2001 |
1 |
| 25 |
11560871 | Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. | 2001 Oct |
3 |
| 26 |
11694260 | CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase. | 2001 Nov |
1 |
| 27 |
10886465 | Pharmacogenetics and psychopharmacotherapy. | 2000 Jun |
1 |
| 28 |
11038161 | Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. | 2000 Nov |
3 |
| 29 |
10411572 | A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. | 1999 Aug |
1 |
| 30 |
10613621 | Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. | 1999 Dec |
2 |
| 31 |
9923577 | Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. | 1998 Nov-Dec |
1 |
| 32 |
9263374 | Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity. | 1997 Aug |
1 |
| 33 |
9435993 | Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. | 1997 Dec |
2 |
| 34 |
8904619 | The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. | 1996 Oct |
1 |
| 35 |
8905790 | [Pharmacokinetics of zotepine and various factors affecting that of zotepine]. | 1996 Apr |
1 |
| 36 |
8923565 | Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug. | 1996 Oct |
1 |
| 37 |
8930576 | Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. | 1996 Oct |
2 |
| 38 |
7628184 | Interethnic difference in omeprazole's inhibition of diazepam metabolism. | 1995 Jul |
1 |
| 39 |
8521680 | Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. | 1995 Sep |
2 |
| 40 |
8806399 | Cytochrome P450 isozymes and antiepileptic drug interactions. | 1995 |
1 |